ABN Amro Equity Research Report Released for Mesoblast Limited (ASX:MSB)

  Melbourne, Australia, Sept 1, 2008 - (ABN Newswire) - Mesoblast Limited's (ASX:MSB)(OTC:MBLTY) product has statistically significant higher fusion rates in anterior cervical interbody operations compared to a competitor. We believe the competitor's FY08 cervical fusion sales were cA & #36;325m, but has recently been forced to exit the market.Mesoblast (MSB.AX): FY08: spinal shockLong term (12 months): BuyTarget price: A & #36;1.50 (from A & #36;1.30)Reason:  

Sydney

  [ Change ]
 
Today

Min: 12°
Max: 18°
Morning rain.
Tomorrow

Min: 10°
Max: 18°
Windy. Sunny.
 

Account

Login

To access your account and listings



Remember me
   
   
   
 
 
Find Hunter Valley accommodation online